BCC1
MCID: BSL024
MIFTS: 59

Basal Cell Carcinoma 1 (BCC1)

Categories: Cancer diseases, Genetic diseases, Mental diseases, Rare diseases, Respiratory diseases, Skin diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Basal Cell Carcinoma 1

MalaCards integrated aliases for Basal Cell Carcinoma 1:

Name: Basal Cell Carcinoma 1 57
Basal Cell Carcinoma, Susceptibility to, 1 57 28 12 5
Basal Cell Carcinoma 73 71
Carcinoma, Basal Cell, Susceptibility to, Type 1 38
Experimental Organism Basal Cell Carcinoma 71
Non-Syndromic Basal Cell Carcinoma 73
Basal Cell Carcinoma, Multiple 71
Multiple Basal Cell Carcinoma 73
Bcc1 57
Bcc 73

Classifications:



External Ids:

OMIM® 57 605462
MeSH 43 D002280
SNOMED-CT via HPO 69 1338007 254701007 275265005
UMLS 71 C0007117 C1854245 C3811653

Summaries for Basal Cell Carcinoma 1

OMIM®: 57 Cutaneous basal cell carcinoma (BCC) is the most common cancer among people of European ancestry (Stacey et al., 2009). The primary environmental risk factor for BCC is sun exposure, but genetics also has a substantial role. Some of the sequence variants that confer susceptibility seem to operate through their association with fair-pigmentation traits common among Europeans, resulting in reduced protection from the damaging effects of ultraviolet (UV) radiation. Other sequence variants have no obvious role in pigmentation or UV susceptibility but instead seem to operate in the contexts of growth and differentiation of the basal layers of the skin (Stacey et al., 2008; Epstein, 2008; Gudbjartsson et al., 2008; Rafnar et al., 2009). See ASIP (600201), TYR (606933), and SHEP5 (227240) for examples of basal cell carcinoma associated with fair skin or sensitivity to sun. Basal cell carcinoma occurs as a feature of multiple syndromes, including basal cell nevus syndrome (BCNS; 109400), Bazex syndrome (301845), Rombo syndrome (180730), Brooke-Spiegler syndrome (605041), Muir-Torre syndrome (158320), and xeroderma pigmentosum (see 278700). Abnormalities in the Hedgehog signaling pathway are found in basal cell carcinomas; see SHH (600725) and SMOH (601500). (605462) (Updated 08-Dec-2022)

MalaCards based summary: Basal Cell Carcinoma 1, also known as basal cell carcinoma, susceptibility to, 1, is related to fibroepithelial basal cell carcinoma and basal cell nevus syndrome. An important gene associated with Basal Cell Carcinoma 1 is PTCH1 (Patched 1), and among its related pathways/superpathways are G-Beta Gamma Signaling and Presynaptic function of Kainate receptors. The drugs Imiquimod and Antiviral Agents have been mentioned in the context of this disorder. Affiliated tissues include skin, endothelial and breast, and related phenotype is basal cell carcinoma.

UniProtKB/Swiss-Prot: 73 A common malignant skin neoplasm that typically appears on hair- bearing skin, most commonly on sun-exposed areas. BCC is slow growing and rarely metastasizes, but has potentialities for local invasion and destruction. It usually develops as a flat, firm, pale area that is small, raised, pink or red, translucent, shiny, and waxy, and the area may bleed following minor injury. Tumor size can vary from a few millimeters to several centimeters in diameter.

Related Diseases for Basal Cell Carcinoma 1

Diseases in the Small Cell Carcinoma family:

Basal Cell Carcinoma 1 Basal Cell Carcinoma 2
Basal Cell Carcinoma 3 Basal Cell Carcinoma 4
Basal Cell Carcinoma 5 Basal Cell Carcinoma 6
Basal Cell Carcinoma 7 Basal Cell Carcinoma
Large Cell Carcinoma Basal Cell Carcinoma, Multiple

Diseases related to Basal Cell Carcinoma 1 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 759)
# Related Disease Score Top Affiliating Genes
1 fibroepithelial basal cell carcinoma 32.1 PTCH2 PTCH1
2 basal cell nevus syndrome 32.0 SMO PTCH2 PTCH1 LOC100507346
3 basal cell carcinoma, multiple 31.8 RASA1 PTCH1 LOC100507346 CCNH
4 focal dermal hypoplasia 30.9 PTCH2 PTCH1
5 basosquamous carcinoma 30.7 PTCH2 PTCH1
6 ameloblastoma 30.3 SMO PTCH1
7 basal cell carcinoma 30.1 SMO RASA1 PTCH2 PTCH1 BCC1
8 medulloblastoma 30.1 SMO PTCH2 PTCH1 LOC100507346
9 congenital hydrocephalus 30.0 PTCH1 LOC100507346
10 klippel-trenaunay-weber syndrome 29.9 RASA1 CCNH
11 overgrowth syndrome 29.8 PTCH1 LOC100507346
12 desmoplastic nodular medulloblastoma 29.7 PTCH2 PTCH1
13 meningioma, familial 29.7 SMO PTCH2 PTCH1
14 nodular basal cell carcinoma 11.9
15 basal cell carcinoma, infundibulocystic 11.8
16 superficial basal cell carcinoma 11.7
17 pigmented basal cell carcinoma 11.7
18 metatypical basal cell carcinoma 11.7
19 follicular basal cell carcinoma 11.7
20 cystic basal cell carcinoma 11.7
21 adenoid basal cell carcinoma 11.7
22 micronodular basal cell carcinoma 11.7
23 anal margin basal cell carcinoma 11.6
24 penis basal cell carcinoma 11.6
25 vulva basal cell carcinoma 11.6
26 morpheaform basal cell carcinoma 11.6
27 basal cell carcinoma 7 11.6
28 external ear basal cell carcinoma 11.5
29 skin nasal cell carcinoma with sebaceous differentiation 11.5
30 scrotum basal cell carcinoma 11.5
31 sarcomatoid basal cell carcinoma 11.5
32 basal cell carcinoma 2 11.5
33 clear cell basal cell carcinoma 11.5
34 basal cell carcinoma 5 11.5
35 basal cell carcinoma 3 11.5
36 basal cell carcinoma 6 11.5
37 basal cell carcinoma 4 11.5
38 signet ring basal cell carcinoma 11.5
39 vulvar basal cell carcinoma 11.5
40 infiltrative basal cell carcinoma 11.5
41 adamantinoid basal cell epithelioma 11.4
42 bap1 tumor predisposition syndrome 11.3
43 trichoepithelioma, multiple familial, 1 11.3
44 9q22.3 microdeletion 11.3
45 bazex syndrome 11.2
46 keratocystic odontogenic tumor 11.2
47 prostate cancer 11.2
48 inflammatory linear verrucous epidermal nevus 11.2
49 rothmund-thomson syndrome, type 2 11.1
50 prostate cancer, hereditary, 1 11.1

Graphical network of the top 20 diseases related to Basal Cell Carcinoma 1:



Diseases related to Basal Cell Carcinoma 1

Symptoms & Phenotypes for Basal Cell Carcinoma 1

Human phenotypes related to Basal Cell Carcinoma 1:

30
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 basal cell carcinoma 30 HP:0002671

Clinical features from OMIM®:

605462 (Updated 08-Dec-2022)

Drugs & Therapeutics for Basal Cell Carcinoma 1

Drugs for Basal Cell Carcinoma 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 179)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Imiquimod Approved, Investigational Phase 4 99011-02-6 57469
2 Antiviral Agents Phase 4
3 Immunologic Factors Phase 4
4 polysaccharide-K Phase 4
5 Adjuvants, Immunologic Phase 4
6 interferons Phase 4
7 Interferon-alpha Phase 4
8
Fluorouracil Approved Phase 2, Phase 3 51-21-8 3385
9
Calcipotriol Approved Phase 2, Phase 3 112965-21-6 5288783
10
Verteporfin Approved, Investigational Phase 3 129497-78-5 5362420
11 Tea Phase 2, Phase 3
12 Antimetabolites Phase 2, Phase 3
13 Immunosuppressive Agents Phase 2, Phase 3
14 Calcium, Dietary Phase 3
15 Anesthetics Phase 3
16
Calcium Nutraceutical Phase 3 7440-70-2 271
17
Acetylcysteine Approved, Investigational Phase 2 616-91-1 581 12035
18
Bevacizumab Approved, Investigational Phase 2 216974-75-3 135329020
19
Cetuximab Approved Phase 1, Phase 2 205923-56-4
20
Erlotinib Approved, Investigational Phase 1, Phase 2 183319-69-9, 183321-74-6 176870
21
Irinotecan Approved, Investigational Phase 2 97682-44-5, 100286-90-6 60838
22
Itraconazole Approved, Investigational Phase 2 84625-61-6 55283
23
Arsenic trioxide Approved, Investigational Phase 1, Phase 2 1327-53-3 518740
24
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
25
Clotrimazole Approved, Vet_approved Phase 2 23593-75-1 2812
26
Oxaliplatin Approved, Investigational Phase 2 61825-94-3 43805 11947679 6857599
27
Benzoic acid Approved, Investigational Phase 2 65-85-0 243
28
Diclofenac Approved, Vet_approved Phase 2 15307-86-5, 15307-79-6 3033
29
Cisplatin Approved Phase 1, Phase 2 15663-27-1 2767 5702198 441203
30
Aminolevulinic acid Approved Phase 2 106-60-5 137
31
Nivolumab Approved Phase 2 946414-94-4
32
Ipilimumab Approved Phase 2 477202-00-9
33
Talimogene laherparepvec Approved, Experimental, Investigational Phase 2 1187560-31-1
34
Ethanol Approved Phase 2 64-17-5 702
35
Hydrogen peroxide Approved, Vet_approved Phase 2 7722-84-1 784
36
Hyaluronic acid Approved, Vet_approved Phase 2 9004-61-9 53477741
37
Carboplatin Approved Phase 2 41575-94-4 10339178 38904
38
Etoposide Approved Phase 2 33419-42-0 36462
39
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
40
Vincristine Approved, Investigational Phase 2 2068-78-2, 57-22-7 5978
41
Picropodophyllin Approved, Investigational Phase 2 518-28-5, 477-47-4 10607 72435
42
Levoleucovorin Approved, Experimental, Investigational Phase 2 68538-85-2, 58-05-9, 73951-54-9 149436 6006
43
Methotrexate Approved Phase 2 1959-05-2, 59-05-2 4112 126941
44
Cemiplimab Approved, Investigational Phase 2 1801342-60-8
45
Calcitriol Approved, Nutraceutical Phase 2 32222-06-3 5280453
46
Aspartic acid Approved, Nutraceutical Phase 1, Phase 2 56-84-8 5960
47
Arginine Approved, Investigational, Nutraceutical Phase 1, Phase 2 74-79-3 6322
48
Glycine Approved, Nutraceutical, Vet_approved Phase 1, Phase 2 56-40-6 750
49
Folic acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
50
Asparagine Approved, Investigational, Nutraceutical Phase 1, Phase 2 70-47-3 6267

Interventional clinical trials:

(show top 50) (show all 260)
# Name Status NCT ID Phase Drugs
1 Treatment of Superficial Basal Cell Carcinoma by Topical Photodynamic Therapy With Fractionated 5-aminolevulinic Acid 20% Versus Two Stage Topical Photodynamic Therapy With Methylaminolevulinate Unknown status NCT01491711 Phase 4 Methylaminolevulinate PDT in 2 sessions;Fractionated 5-aminolevulinic acid hydrochloride 20% gel PDT
2 Imiquimod 5% Cream for the Treatment of Periocular Basal Cell Carcinoma Unknown status NCT00803907 Phase 4 Imiquimod 5% cream
3 Study of the Relationship Between the Pharmacokinetics of Vismodegib and Safety Data: a Pilot Study to Therapeutic Optimization in Patients With Basal Cell Carcinoma - OPTIVISMO-1 Completed NCT03610022 Phase 4 Treatment with vismodegib
4 Intron-A/Aldara Combination Therapy for BCC Excluding the Face and Scalp Completed NCT00581425 Phase 4
5 Topical Imiquimod 5% Cream in the Treatment of Nodular Basal Cell Carcinoma After Initial Treatment With Curettage Completed NCT00314756 Phase 4 imiquimod
6 VISmodegib for ORbital and Periocular Basal Cell Carcinoma (VISORB) Completed NCT02436408 Phase 4 Vismodegib
7 A Randomized Open Label Study to Evaluate the Safety and Efficacy if Imiquimod 5% Cream Applied 3 Times Per Week for 8 or 12 Weeks in the Treatment of Low Risk Nodular Basal Cell Carcinoma Completed NCT00204555 Phase 4 Imiquimod
8 A Randomized Clinical Trial in the Surgical Treatment of Basal Cell Carcinoma of the Eyelid: Surgical Excision With Frozen Section vs. Permanent Section Control Unknown status NCT00663650 Phase 3
9 A Multicenter, Phase III, Double Blind Study of Photodynamic Therapy (PDT) With Metvix 160 mg/g Cream in Comparison to PDT With Placebo Cream in Patients With Primary Nodular Basal Cell Carcinoma Completed NCT00472108 Phase 3
10 A Multicentre, Phase III, Double Blind Study of Photodynamic Therapy (PDT) With Metvix® 160 mg/g Cream in Comparison to PDT With Placebo Cream in Patients With Primary Nodular Basal Cell Carcinoma. Completed NCT00472043 Phase 3
11 An Open Multicenter, Phase III Study of Photodynamic Therapy With Metvix Cream 160 mg/g in Patients With "High Risk" Basal Cell Carcinoma Completed NCT00473343 Phase 3
12 A Randomized, Observer Blind, Multinational Phase III Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) in Comparison to Metvix® in the Treatment of Non-aggressive Basal Cell Carcinoma (BCC) With Photodynamic Therapy (PDT) Completed NCT02144077 Phase 3 BF-200 ALA;methyl-aminolevulinate
13 A Multicentre, Randomised Study of Photodynamic Therapy(PDT) With Metvix® 160 mg/g Cream in Immuno-compromised Patients With Non-melanoma Skin Cancer Completed NCT00472459 Phase 3
14 A Multicenter, Phase III, Randomised Study of Photodynamic Therapy With Metvix Cream 160 mg/g in Comparison With Cryotherapy in Patients With Primary Superficial Basal Cell Carcinoma Completed NCT00469417 Phase 3
15 An Open-label Study to Evaluate the Safety and Long-Term Clinical Efficacy of Imiquimod 5% Cream Applied Once Daily 7 Days Per Week for 6 Weeks in the Treatment of Superficial Basal Cell Carcinoma Completed NCT00189306 Phase 3 Imiquimod 5% cream
16 An Open-Label Study to Evaluate the Safety and Long-Term Clinical Efficacy of Imiquimod 5% Cream Applied Once Daily 5 Days Per Week for 6 Weeks in the Treatment of Superficial Basal Cell Carcinoma Completed NCT00189241 Phase 3 imiquimod
17 Open-label Study to Evaluate the Use of Imiquimod 5% Cream for Reducing Postsurgical Recurrence or Persistence of Basal Cell Carcinoma Following Excision by Curettage Completed NCT00129519 Phase 3 Imiquimod 5% cream
18 Conventional Versus Fractional CO2 Laser Assisted Photodynamic Therapy for Basal Call Carcinomas and Actinic Keratoses Completed NCT01260987 Phase 2, Phase 3 Conventional photodynamic therapy;Fractional CO2 laser assisted PDT
19 Open Label, Randomized Comparison of Two Schemes of Cryosurgery and Imiquimod Combination Treatment for Basal Cell Carcinoma of the Skin Completed NCT01212549 Phase 3
20 Topical Sinecatechins Ointment in Treatment of Primary Superficial Basal Cell Carcinoma: a Double Blind, Randomized, Placebo-controlled Trial. Completed NCT02029352 Phase 2, Phase 3 Sinecatechins 10%;Placebo
21 A Randomized Controlled Trial of Excisional Surgery Versus Imiquimod 5% Cream for Nodular and Superficial Basal Cell Carcinoma Completed NCT00066872 Phase 3 imiquimod
22 Open Study to Evaluate the Efficacy and Tolerance of Imiquimod 5% Cream for the Treatment of a Large and/or Multiple Superficial Basal Cell Carcinoma. Completed NCT00189280 Phase 3 Imiquimod
23 Calcium Electroporation for Basal Cell Carcinomas - Proof of Concept Study Recruiting NCT05046262 Phase 3 Calcium chloride
24 A Randomized, Double Blind, Vehicle-controlled Multicenter Phase III Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the Treatment of Superficial Basal Cell Carcinoma (sBCC) With Photodynamic Therapy (PDT). Recruiting NCT03573401 Phase 3
25 Combination of 5-Fluorouracil and Calcipotriene in the Treatment of Superficial Basal Cell Carcinomas and Squamous Cell Carcinomas in Situ Recruiting NCT05381597 Phase 2, Phase 3 Combination cream of 5-fluorouracil and calcipotriene;5-fluorouracil cream
26 Surgical Excision Versus Combined Treatment With Curettage and Imiquimod for Nodular Basal Cell Carcinoma: an Open, Non-inferiority, Randomized Controlled Trial Active, not recruiting NCT02242929 Phase 3 Imiquimod 5% cream with prior curettage
27 CSP #2019 - Basal Cell Carcinoma Chemoprevention Trial (B3C) Not yet recruiting NCT05212246 Phase 3 5% Imiquimod cream;Placebo Vehicle Control Cream
28 A Randomized, Placebo-Controlled, Masked, Multicenter Phase III Study Of Photodynamic Therapy With Verteporfin For Injection (VFI) For The Treatment Of Multiple Basal Cell Carcinoma Terminated NCT00049959 Phase 3 verteporfin PDT
29 A Randomized, Double-blind, Vehicle-controlled, Multicenter Trial of Topically Administered LDE225 Cream (0.75% Bid) to Evaluate Clearance of Basal Cell Carcinoma in Adult Patients With Nevoid Basal Cell Carcinoma Syndrome Withdrawn NCT03070691 Phase 2, Phase 3 LDE225B;Vehicle
30 Investigation of the Effectiveness of Non-Coherent Blue Light in Intralesional Photodynamic of Basal Cell Carcinoma Unknown status NCT00747903 Phase 2 aminolevulinic acid hydrochloride
31 Open, Prospective, Single-center Study Evaluating the Efficacy and Safety of 0.05% Ingenol Mebutate (Picato® 500) in the Treatment of Basal Cell Carcinoma Unknown status NCT03546166 Phase 2 Picato 0.05% Topical Gel
32 A Randomized, Double-Blind Pilot Study of N-Acetylcysteine Mucoadherent Rinse Versus Placebo for Thickened Secretions and Mucositis Secondary to Chemoradiotherapy in the Management of Head and Neck Malignancies Completed NCT02123511 Phase 2 acetylcysteine
33 A Randomized Phase II Trial of Bevacizumab to Control Brain Radiation Damage Completed NCT00492089 Phase 2 bevacizumab;placebo
34 A Phase I, and Biologic Correlative Study of Erlotinib, in Combination With Cetuximab and Bevacizumab in Patients With Metastatic Renal Cell Carcinoma Completed NCT00101348 Phase 1, Phase 2 erlotinib hydrochloride
35 A Phase II, Double-blind, Randomized, Proof-of-Concept, Dose-ranging Trial Evaluating the Efficacy, Safety and Pharmacokinetics of Oral LDE225 in Treatment of Adult Patients With Nevoid Basal Cell Carcinoma Syndrome Completed NCT01350115 Phase 2 LDE225;Placebo
36 A Pivotal Phase II, Multicenter, Single-arm, Two-cohort Trial Evaluating the Efficacy and Safety of GDC-0449 in Patients With Advanced Basal Cell Carcinoma Completed NCT00833417 Phase 2 Vismodegib 150 mg
37 A Phase 1b Open Label Study of Pembrolizumab for Unresectable or Metastatic Basal Cell Carcinoma Completed NCT02690948 Phase 1, Phase 2 Vismodegib
38 An Open-label, Multi-center, Dose-escalation, Cohort Study to Determine the Maximum Tolerated Dose and Safety of PEP005 Topical Gel Given as Either a Single Application (on Day 1) or as Two Applications (on Day 1 and Day 8) to a Superficial Basal Cell Carcinoma (sBCC) on the Trunk. Completed NCT00432185 Phase 2 PEP005
39 Phase IIa Trial With PD-L1 IO103 Vaccination With Montanide in Patients With Basal Cell Carcinoma Completed NCT03714529 Phase 2
40 Phase II Study Evaluating the Interest of Vismodegib as Neo-adjuvant Treatment of Basal Cell Carcinoma (BCC) Completed NCT02667574 Phase 2 ERIVEDGE
41 A Phase II, Single-armed, Multicenter Trial of Neoadjuvant Vismodegib in Patients With Large and/or Recurrent Resectable Basal Cell Carcinoma Completed NCT03035188 Phase 2 Vismodegib
42 A Phase II Study of Radiation Therapy and Vismodegib, for the Treatment of Locally Advanced Basal Cell Carcinoma of the Head and Neck Completed NCT01835626 Phase 2 Vismodegib
43 A Phase 1/2a Study of the Efficacy and Safety of ASN-002 Alone or in Combination With 5-FU in Adult Patients With Low-risk Nodular Basal Cell Carcinoma Completed NCT02550678 Phase 1, Phase 2 5-FU
44 ML28485:Phase 2B Single-site,Open-label,Nonrandomized Study Evaluating Efficacy of Oral Vismodegib in Various Histologic Subtypes (Infiltrative/Morpheaform,Nodular and Superficial)of High Risk and/or Locally Advanced Basal Cell Carcinoma Completed NCT01700049 Phase 2 vismodegib (150 mg PO daily)
45 An Open-label, Multicenter Extension Study of GDC-0449 (Hedgehog Pathway Inhibitor) in Patients Treated With GDC-0449 in a Previous Genentech-sponsored Phase I or Phase II Cancer Study Completed NCT00959647 Phase 2 Vismodegib;FOLFOX;FOLFIRI;Bevacizumab
46 Phase IIb Open-label Trial of SUBA™-Itraconazole in Subjects With Basal Cell Carcinoma Nevus Syndrome (BCCNS) Completed NCT02354261 Phase 2 SUBA-Itraconazole
47 Pilot Biomarker Trial to Evaluate the Efficacy of Itraconazole in Patients With Basal Cell Carcinomas Completed NCT01108094 Phase 2 Itraconazole
48 A Multi-Center, Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled Study to Determine the Safety of PEP005 0.0025%, 0.01% and 0.05% Gel With Two Treatment Schedules, Day 1 & 2 or Day 1 & 8 Applications to Superficial Basal Cell Carcinoma Completed NCT00108134 Phase 2 PEP005
49 A Multi-center, Randomized, Double-blind, Parallel-group, Vehicle-controlled Study to Determine the Safety of PEP005 0.0025%, 0.01% and 0.05% Gel With Two Treatment Schedules, Day 1 & 2 or Day 1 & 8 Applications to Nodular Basal Cell Carcinoma Completed NCT00108121 Phase 2 PEP005
50 A Phase IIb Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Topical Bacteriophage T4 Endonuclease V in Renal Allograft Recipients With a History of Non-melanoma Skin Cancer Completed NCT00089180 Phase 2 liposomal T4N5 lotion

Search NIH Clinical Center for Basal Cell Carcinoma 1

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Fluorouracil

Genetic Tests for Basal Cell Carcinoma 1

Genetic tests related to Basal Cell Carcinoma 1:

# Genetic test Affiliating Genes
1 Basal Cell Carcinoma, Susceptibility to, 1 28 PTCH1 PTCH2 RASA1 SMO

Anatomical Context for Basal Cell Carcinoma 1

Organs/tissues related to Basal Cell Carcinoma 1:

MalaCards : Skin, Endothelial, Breast, Lung, Kidney, Lymph Node, Brain

Publications for Basal Cell Carcinoma 1

Articles related to Basal Cell Carcinoma 1:

(show top 50) (show all 12921)
# Title Authors PMID Year
1
A slow-cycling LGR5 tumour population mediates basal cell carcinoma relapse after therapy. 62 57
30297799 2018
2
A cell identity switch allows residual BCC to survive Hedgehog pathway inhibition. 62 57
30297801 2018
3
Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. 62 57
19726763 2009
4
New common variants affecting susceptibility to basal cell carcinoma. 62 57
19578363 2009
5
Sequence variants at the TERT-CLPTM1L locus associate with many cancer types. 62 57
19151717 2009
6
Common variants on 1p36 and 1q42 are associated with cutaneous basal cell carcinoma but not with melanoma or pigmentation traits. 62 57
18849993 2008
7
Pathological responses to oncogenic Hedgehog signaling in skin are dependent on canonical Wnt/beta3-catenin signaling. 62 57
19165927 2008
8
ASIP and TYR pigmentation variants associate with cutaneous melanoma and basal cell carcinoma. 62 57
18488027 2008
9
Cutaneous basal cell carcinomas: distinct host factors are associated with the development of tumors on the trunk and on the head and neck. 62 57
11466690 2001
10
Nonsyndromic type of hereditary multiple basal cell carcinoma. 62 57
11078568 2000
11
Isolation and characterization of human patched 2 (PTCH2), a putative tumour suppressor gene inbasal cell carcinoma and medulloblastoma on chromosome 1p32. 62 57
9931336 1999
12
The role of the human homologue of Drosophila patched in sporadic basal cell carcinomas. 62 57
8782823 1996
13
Basal cell carcinomas: attack of the hedgehog. 57
18813320 2008
14
Identification of mutations in the human PATCHED gene in sporadic basal cell carcinomas and in patients with the basal cell nevus syndrome. 57
9620294 1998
15
Nonsense mutations in the C-terminal SH2 region of the GTPase activating protein (GAP) gene in human tumours. 57
8275088 1993
16
Sonidegib improved quality of life in patients with advanced basal cell carcinoma: Results from the phase 2 Basal cell carcinoma outcomes with LDE225 treatment trial through 73 weeks. 62
36425794 2023
17
Prevalence of and Associated Factors for Eyelid Cancer in the American Academy of Ophthalmology Intelligent Research in Sight Registry. 62
36439695 2023
18
Gallic acid has an inhibitory effect on skin squamous cell carcinoma and acts on the heat shock protein HSP90AB1. 62
36375658 2023
19
Relationship between actinic keratosis and malignant skin lesions on the eyelid. 62
35170648 2023
20
Basal Cell Carcinoma. 62
36410973 2023
21
Reply to "Local recurrence of clinically observed basal cell carcinoma…". 62
36113617 2022
22
Use of Cytokeratin 17 in the Differentiation Between Desmoplastic Trichilemmoma and Cutaneous Basal Cell Carcinoma. 62
36197047 2022
23
Complete pathologic clearance with vismodegib in advanced basal cell carcinoma of the scalp with cranial invasion. 62
36310643 2022
24
Safety and efficacy of nivolumab, an anti-PD1 immunotherapy, in patients with advanced basal cell carcinoma, after failure or intolerance to sonic Hedgehog inhibitors: UNICANCER AcSé NIVOLUMAB trial. 62
36335780 2022
25
Update in the treatment of non-melanoma skin cancers: the use of PD-1 inhibitors in basal cell carcinoma and cutaneous squamous-cell carcinoma. 62
36455990 2022
26
I need an exact margin measurement for this basal cell carcinoma! 62
34969782 2022
27
LY6D marks pre-existing resistant basosquamous tumor subpopulations. 62
36473848 2022
28
Mohs micrographic surgery for periocular skin cancer: a single-institution experience. 62
36464757 2022
29
Variations in genetics, biology, and phenotype of cutaneous disorders in skin of color. Part II: Differences in clinical presentation and disparities in cutaneous disorders in skin of color. 62
35817332 2022
30
Variations in genetics, biology, and phenotype of cutaneous disorders in skin of color - Part I: Genetic, biologic, and structural differences in skin of color. 62
35809800 2022
31
Basal Cell Carcinomas After Radiotherapy Show More Frequent Follicular Differentiation Than Tumors From Sun-Exposed Areas: Immunohistochemical Study With a Special Focus on Infundibulocystic Basal Cell Carcinoma. 62
36395444 2022
32
Germline intergenic duplications at Xq26.1 underlie Bazex-Dupré-Christol basal cell carcinoma susceptibility syndrome. 62
35986704 2022
33
Basal Cell Carcinoma: A Narrative Review on Contemporary Diagnosis and Management. 62
35729457 2022
34
Skin Cancer in Solid Organ Transplant Recipients: A Review for the Nondermatologist. 62
36334939 2022
35
Photodynamic therapy with light emitting fabrics: a review. 62
34797414 2022
36
Patched and Costal-2 mutations lead to differences in tissue overgrowth autonomy. 62
35468034 2022
37
Dimethyl sulfoxide (DMSO): a solvent that may solve selected cutaneous clinical challenges. 62
36459193 2022
38
Characterizing Skin Cancer in Transplant Recipients by Fitzpatrick Skin Phototype. 62
36469283 2022
39
Uncertainty estimation for margin detection in cancer surgery using mass spectrometry. 62
36175747 2022
40
Towards less mutilating treatments in patients with advanced non-melanoma skin cancers by earlier use of immune checkpoint inhibitors. 62
36257534 2022
41
A case of head and neck cutaneous squamous cell carcinoma highlighting aggressive perineural features. 62
36189160 2022
42
Quantitative analysis of Merkel cell polyomavirus (MCPyV) genome in non-melanoma skin cancer and normal tumor margins. 62
36279096 2022
43
Caruncular lesions: A 16-year single centre review in the United Kingdom. 62
36366790 2022
44
Reflectance confocal microscopy of facial neoplasms: Follicular involvement as a clue to diagnosis. 62
36321579 2022
45
Double Primary Malignancies Involving Cutaneous Carcinoma. 62
36409851 2022
46
Clinicopathological features of patients with wide local excision of eyelid malignant neoplasms: a more than five years retrospective study from China. 62
36376823 2022
47
A case of racemiform trichoblastoma in a dog. 62
36318021 2022
48
The effect of menopausal hormone therapy on the risk of melanoma and keratinocyte skin cancer: A systematic review and meta-analysis of observational studies. 62
36372010 2022
49
Preoperative and postoperative evaluation of survivin in peripheral blood of patients with non-melanoma skin cancers. A pilot study. 62
36369849 2022
50
Early detection and prevention of head and neck cancers. 62
36369552 2022

Variations for Basal Cell Carcinoma 1

ClinVar genetic disease variations for Basal Cell Carcinoma 1:

5 (show all 38)
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 RASA1, CCNH NM_002890.3(RASA1):c.656C>G (p.Ser219Ter) SNV Pathogenic
464870 rs1554044823 GRCh37: 5:86627281-86627281
GRCh38: 5:87331464-87331464
2 RASA1, CCNH NM_002890.3(RASA1):c.2131C>T (p.Arg711Ter) SNV Pathogenic
213660 rs863223718 GRCh37: 5:86672329-86672329
GRCh38: 5:87376512-87376512
3 PTCH1 NM_000264.5(PTCH1):c.938C>G (p.Ser313Ter) SNV Pathogenic
576491 rs1564055259 GRCh37: 9:98242679-98242679
GRCh38: 9:95480397-95480397
4 PTCH1, LOC100507346 NM_000264.5(PTCH1):c.2380C>T (p.Gln794Ter) SNV Pathogenic
931311 rs1840094606 GRCh37: 9:98229578-98229578
GRCh38: 9:95467296-95467296
5 RASA1, CCNH NM_002890.3(RASA1):c.2925+1G>A SNV Likely Pathogenic
931156 rs1762099168 GRCh37: 5:86682721-86682721
GRCh38: 5:87386904-87386904
6 PTCH1 NM_000264.5(PTCH1):c.3337C>T (p.Arg1113Cys) SNV Uncertain Significance
823625 rs758520331 GRCh37: 9:98215872-98215872
GRCh38: 9:95453590-95453590
7 PTCH1 NM_000264.5(PTCH1):c.4178C>T (p.Pro1393Leu) SNV Uncertain Significance
931606 rs1368334005 GRCh37: 9:98209360-98209360
GRCh38: 9:95447078-95447078
8 PTCH1 NM_000264.5(PTCH1):c.1067+5G>C SNV Uncertain Significance
237448 rs372657547 GRCh37: 9:98242246-98242246
GRCh38: 9:95479964-95479964
9 PTCH2 NM_003738.5(PTCH2):c.3347C>T (p.Pro1116Leu) SNV Uncertain Significance
453938 rs539161089 GRCh37: 1:45288751-45288751
GRCh38: 1:44823079-44823079
10 PTCH2 NM_003738.5(PTCH2):c.565C>G (p.Leu189Val) SNV Uncertain Significance
524558 rs747885797 GRCh37: 1:45297430-45297430
GRCh38: 1:44831758-44831758
11 PTCH2 NM_003738.5(PTCH2):c.109C>T (p.Arg37Cys) SNV Uncertain Significance
570977 rs768246990 GRCh37: 1:45307675-45307675
GRCh38: 1:44842003-44842003
12 PTCH2 NM_003738.5(PTCH2):c.19C>G (p.Leu7Val) SNV Uncertain Significance
453931 rs1030456781 GRCh37: 1:45308586-45308586
GRCh38: 1:44842914-44842914
13 PTCH1 NM_000264.5(PTCH1):c.68C>A (p.Ala23Asp) SNV Uncertain Significance
930926 rs761204245 GRCh37: 9:98270576-98270576
GRCh38: 9:95508294-95508294
14 PTCH2 NM_003738.5(PTCH2):c.3185T>G (p.Val1062Gly) SNV Uncertain Significance
931578 rs1652996959 GRCh37: 1:45288987-45288987
GRCh38: 1:44823315-44823315
15 PTCH2 NM_003738.5(PTCH2):c.2716G>C (p.Glu906Gln) SNV Uncertain Significance
952970 rs751579508 GRCh37: 1:45292420-45292420
GRCh38: 1:44826748-44826748
16 PTCH1 NM_000264.5(PTCH1):c.4051A>G (p.Asn1351Asp) SNV Uncertain Significance
188148 rs786204103 GRCh37: 9:98209487-98209487
GRCh38: 9:95447205-95447205
17 PTCH1 NM_000264.5(PTCH1):c.4049G>A (p.Arg1350Gln) SNV Uncertain Significance
577136 rs978722722 GRCh37: 9:98209489-98209489
GRCh38: 9:95447207-95447207
18 PTCH1 NM_000264.5(PTCH1):c.4043A>G (p.Asn1348Ser) SNV Uncertain Significance
220391 rs371943557 GRCh37: 9:98209495-98209495
GRCh38: 9:95447213-95447213
19 PTCH1 NM_000264.5(PTCH1):c.4024C>T (p.Arg1342Cys) SNV Uncertain Significance
409167 rs781539921 GRCh37: 9:98209514-98209514
GRCh38: 9:95447232-95447232
20 PTCH1 NM_000264.5(PTCH1):c.3919C>T (p.Pro1307Ser) SNV Uncertain Significance
132753 rs574880967 GRCh37: 9:98209619-98209619
GRCh38: 9:95447337-95447337
21 PTCH1 NM_000264.5(PTCH1):c.3908G>T (p.Arg1303Leu) SNV Uncertain Significance
524547 rs779365332 GRCh37: 9:98209630-98209630
GRCh38: 9:95447348-95447348
22 PTCH1 NM_000264.5(PTCH1):c.3734A>G (p.Gln1245Arg) SNV Uncertain Significance
409208 rs767792734 GRCh37: 9:98211421-98211421
GRCh38: 9:95449139-95449139
23 PTCH1 NM_000264.5(PTCH1):c.3575G>A (p.Arg1192His) SNV Uncertain Significance
486183 rs762040036 GRCh37: 9:98211580-98211580
GRCh38: 9:95449298-95449298
24 PTCH1 NM_000264.5(PTCH1):c.2671G>A (p.Gly891Ser) SNV Uncertain Significance
220717 rs570091335 GRCh37: 9:98224170-98224170
GRCh38: 9:95461888-95461888
25 PTCH1 NM_000264.5(PTCH1):c.2635G>A (p.Asp879Asn) SNV Uncertain Significance
216378 rs750373573 GRCh37: 9:98224206-98224206
GRCh38: 9:95461924-95461924
26 PTCH1, LOC100507346 NM_000264.5(PTCH1):c.2440A>C (p.Asn814His) SNV Uncertain Significance
188150 rs754623561 GRCh37: 9:98229518-98229518
GRCh38: 9:95467236-95467236
27 PTCH1, LOC100507346 NM_000264.5(PTCH1):c.2287G>T (p.Val763Phe) SNV Uncertain Significance
524507 rs544963328 GRCh37: 9:98229671-98229671
GRCh38: 9:95467389-95467389
28 PTCH1, LOC100507346 NM_000264.5(PTCH1):c.1989G>C (p.Gln663His) SNV Uncertain Significance
237462 rs753002023 GRCh37: 9:98231294-98231294
GRCh38: 9:95469012-95469012
29 PTCH1 NM_000264.5(PTCH1):c.1138G>A (p.Glu380Lys) SNV Uncertain Significance
409137 rs772903899 GRCh37: 9:98241359-98241359
GRCh38: 9:95479077-95479077
30 PTCH1 NM_000264.5(PTCH1):c.949C>T (p.Leu317Phe) SNV Uncertain Significance
578248 rs1380199153 GRCh37: 9:98242369-98242369
GRCh38: 9:95480087-95480087
31 PTCH1 NM_000264.5(PTCH1):c.901G>A (p.Asp301Asn) SNV Uncertain Significance
524544 rs767601899 GRCh37: 9:98242716-98242716
GRCh38: 9:95480434-95480434
32 PTCH1 NM_000264.5(PTCH1):c.412C>T (p.Arg138Cys) SNV Uncertain Significance
486174 rs139535966 GRCh37: 9:98248139-98248139
GRCh38: 9:95485857-95485857
33 PTCH1 NM_000264.5(PTCH1):c.181G>A (p.Ala61Thr) SNV Uncertain Significance
409215 rs150069331 GRCh37: 9:98270463-98270463
GRCh38: 9:95508181-95508181
34 PTCH1 NM_000264.5(PTCH1):c.37C>G (p.Arg13Gly) SNV Uncertain Significance
188208 rs779791579 GRCh37: 9:98270607-98270607
GRCh38: 9:95508325-95508325
35 PTCH1 NM_000264.5(PTCH1):c.4162G>A (p.Gly1388Arg) SNV Uncertain Significance
135105 rs587778631 GRCh37: 9:98209376-98209376
GRCh38: 9:95447094-95447094
36 PTCH1 NM_000264.5(PTCH1):c.4138G>A (p.Ala1380Thr) SNV Uncertain Significance
577111 rs111481152 GRCh37: 9:98209400-98209400
GRCh38: 9:95447118-95447118
37 PTCH1 NM_000264.5(PTCH1):c.37C>T (p.Arg13Cys) SNV Uncertain Significance
930369 rs779791579 GRCh37: 9:98270607-98270607
GRCh38: 9:95508325-95508325
38 PTCH1 NM_001083603.3(PTCH1):c.2T>C (p.Met1Thr) SNV Uncertain Significance
930744 rs1039069537 GRCh37: 9:98279101-98279101
GRCh38: 9:95516819-95516819

UniProtKB/Swiss-Prot genetic disease variations for Basal Cell Carcinoma 1:

73
# Symbol AA change Variation ID SNP ID
1 PTCH1 p.Arg1114Trp VAR_007847 rs587776689

Cosmic variations for Basal Cell Carcinoma 1:

8 (show top 50) (show all 3424)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM84510986 ZNF276 skin,NS,carcinoma,basal cell carcinoma c.*940C>T p.? 16:89739186-89739186 19
2 COSM149268805 ZFHX3 skin,NS,carcinoma,basal cell carcinoma c.1261G>A p.G421R 16:72958885-72958885 19
3 COSM87274302 ZFHX3 skin,NS,carcinoma,basal cell carcinoma c.1655C>T p.S552F 16:72958491-72958491 19
4 COSM87270496 ZFHX3 skin,NS,carcinoma,basal cell carcinoma c.10847C>T p.S3616F 16:72787429-72787429 19
5 COSM149259613 ZFHX3 skin,NS,carcinoma,basal cell carcinoma c.10847C>T p.S3616F 16:72787429-72787429 19
6 COSM149268792 ZFHX3 skin,NS,carcinoma,basal cell carcinoma c.5825G>A p.G1942E 16:72796857-72796857 19
7 COSM87274307 ZFHX3 skin,NS,carcinoma,basal cell carcinoma c.1261G>A p.G421R 16:72958885-72958885 19
8 COSM149268800 ZFHX3 skin,NS,carcinoma,basal cell carcinoma c.1655C>T p.S552F 16:72958491-72958491 19
9 COSM87273325 ZFHX3 skin,NS,carcinoma,basal cell carcinoma c.2084C>T p.P695L 16:72958062-72958062 19
10 COSM149304906 ZFHX3 skin,NS,carcinoma,basal cell carcinoma c.1991C>T p.S664F 16:72958155-72958155 19
11 COSM87296537 ZFHX3 skin,NS,carcinoma,basal cell carcinoma c.11050G>A p.D3684N 16:72787226-72787226 19
12 COSM102023150 ZFHX3 skin,NS,carcinoma,basal cell carcinoma c.-23-7526C>T p.? 16:72958491-72958491 19
13 COSM102023155 ZFHX3 skin,NS,carcinoma,basal cell carcinoma c.-23-7920G>A p.? 16:72958885-72958885 19
14 COSM102019420 ZFHX3 skin,NS,carcinoma,basal cell carcinoma c.8105C>T p.S2702F 16:72787429-72787429 19
15 COSM149331772 ZFHX3 skin,NS,carcinoma,basal cell carcinoma c.11050G>A p.D3684N 16:72787226-72787226 19
16 COSM102023144 ZFHX3 skin,NS,carcinoma,basal cell carcinoma c.3083G>A p.G1028E 16:72796857-72796857 19
17 COSM102047764 ZFHX3 skin,NS,carcinoma,basal cell carcinoma c.8308G>A p.D2770N 16:72787226-72787226 19
18 COSM87286441 ZFHX3 skin,NS,carcinoma,basal cell carcinoma c.1991C>T p.S664F 16:72958155-72958155 19
19 COSM102036925 ZFHX3 skin,NS,carcinoma,basal cell carcinoma c.-23-7190C>T p.? 16:72958155-72958155 19
20 COSM149266372 ZFHX3 skin,NS,carcinoma,basal cell carcinoma c.2084C>T p.P695L 16:72958062-72958062 19
21 COSM102022243 ZFHX3 skin,NS,carcinoma,basal cell carcinoma c.-23-7097C>T p.? 16:72958062-72958062 19
22 COSM87274293 ZFHX3 skin,NS,carcinoma,basal cell carcinoma c.5825G>A p.G1942E 16:72796857-72796857 19
23 COSM104882801 XPO1 skin,NS,carcinoma,basal cell carcinoma c.782G>A p.R261Q 2:61496985-61496985 19
24 COSM104236272 XPO1 skin,NS,carcinoma,basal cell carcinoma c.782G>A p.R261Q 2:61496985-61496985 19
25 COSM101976974 XPO1 skin,NS,carcinoma,basal cell carcinoma c.782G>A p.R261Q 2:61496985-61496985 19
26 COSM87040659 TSC2 skin,NS,carcinoma,basal cell carcinoma c.869C>T p.P290L 16:2058767-2058767 19
27 COSM101179498 TSC2 skin,NS,carcinoma,basal cell carcinoma c.1913C>T p.S638F 16:2071897-2071897 19
28 COSM150324396 TSC2 skin,NS,carcinoma,basal cell carcinoma c.869C>T p.P290L 16:2058767-2058767 19
29 COSM101191558 TSC2 skin,NS,carcinoma,basal cell carcinoma c.722C>T p.P241L 16:2058767-2058767 19
30 COSM147706701 TSC2 skin,NS,carcinoma,basal cell carcinoma c.869C>T p.P290L 16:2058767-2058767 19
31 COSM150353664 TSC2 skin,NS,carcinoma,basal cell carcinoma c.2060C>T p.S687F 16:2071897-2071897 19
32 COSM151748023 TSC2 skin,NS,carcinoma,basal cell carcinoma c.679T>A p.C227S 16:2056674-2056674 19
33 COSM150576157 TSC2 skin,NS,carcinoma,basal cell carcinoma c.679T>A p.C227S 16:2056674-2056674 19
34 COSM149802478 TSC2 skin,NS,carcinoma,basal cell carcinoma c.679T>A p.C227S 16:2056674-2056674 19
35 COSM148980439 TSC2 skin,NS,carcinoma,basal cell carcinoma c.2060C>T p.S687F 16:2071897-2071897 19
36 COSM90415129 TSC2 skin,NS,carcinoma,basal cell carcinoma c.869C>T p.P290L 16:2058767-2058767 19
37 COSM149800636 TSC2 skin,NS,carcinoma,basal cell carcinoma c.2060C>T p.S687F 16:2071897-2071897 19
38 COSM148991757 TSC2 skin,NS,carcinoma,basal cell carcinoma c.869C>T p.P290L 16:2058767-2058767 19
39 COSM151753165 TSC2 skin,NS,carcinoma,basal cell carcinoma c.869C>T p.P290L 16:2058767-2058767 19
40 COSM151513825 TSC2 skin,NS,carcinoma,basal cell carcinoma c.679T>A p.C227S 16:2056674-2056674 19
41 COSM151371066 TSC2 skin,NS,carcinoma,basal cell carcinoma c.679T>A p.C227S 16:2056674-2056674 19
42 COSM148982237 TSC2 skin,NS,carcinoma,basal cell carcinoma c.679T>A p.C227S 16:2056674-2056674 19
43 COSM136628294 TSC2 skin,NS,carcinoma,basal cell carcinoma c.902C>T p.P301L 16:2058767-2058767 19
44 COSM110103971 TSC2 skin,NS,carcinoma,basal cell carcinoma c.568T>A p.C190S 16:2056674-2056674 19
45 COSM150583851 TSC2 skin,NS,carcinoma,basal cell carcinoma c.869C>T p.P290L 16:2058767-2058767 19
46 COSM102616914 TSC2 skin,NS,carcinoma,basal cell carcinoma c.2060C>T p.S687F 16:2071897-2071897 19
47 COSM136618116 TSC2 skin,NS,carcinoma,basal cell carcinoma c.712T>A p.C238S 16:2056674-2056674 19
48 COSM110102044 TSC2 skin,NS,carcinoma,basal cell carcinoma c.1949C>T p.S650F 16:2071897-2071897 19
49 COSM150574866 TSC2 skin,NS,carcinoma,basal cell carcinoma c.2060C>T p.S687F 16:2071897-2071897 19
50 COSM102629996 TSC2 skin,NS,carcinoma,basal cell carcinoma c.869C>T p.P290L 16:2058767-2058767 19

Expression for Basal Cell Carcinoma 1

Search GEO for disease gene expression data for Basal Cell Carcinoma 1.

Pathways for Basal Cell Carcinoma 1

GO Terms for Basal Cell Carcinoma 1

Cellular components related to Basal Cell Carcinoma 1 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 ciliary membrane GO:0060170 8.92 SMO PTCH1

Biological processes related to Basal Cell Carcinoma 1 according to GeneCards Suite gene sharing:

(show all 17)
# Name GO ID Score Top Affiliating Genes
1 vasculogenesis GO:0001570 9.87 SMO RASA1
2 negative regulation of smoothened signaling pathway GO:0045879 9.8 PTCH2 PTCH1
3 cell fate determination GO:0001709 9.78 PTCH2 PTCH1
4 somite development GO:0061053 9.76 PTCH1 SMO
5 epithelial cell proliferation GO:0050673 9.73 SMO PTCH1
6 cellular response to cholesterol GO:0071397 9.73 PTCH1 SMO
7 heart morphogenesis GO:0003007 9.72 SMO PTCH1
8 mammary gland epithelial cell differentiation GO:0060644 9.71 SMO PTCH1
9 dorsal/ventral pattern formation GO:0009953 9.7 SMO PTCH1
10 embryonic organ development GO:0048568 9.69 SMO PTCH1
11 smooth muscle tissue development GO:0048745 9.67 SMO PTCH1
12 dorsal/ventral neural tube patterning GO:0021904 9.62 SMO PTCH1
13 commissural neuron axon guidance GO:0071679 9.56 SMO PTCH1
14 smoothened signaling pathway GO:0007224 9.55 SMO PTCH2 PTCH1
15 pattern specification process GO:0007389 9.54 SMO PTCH1
16 positive regulation of epidermal cell differentiation GO:0045606 9.26 PTCH2 PTCH1
17 epidermal cell fate specification GO:0009957 8.92 PTCH2 PTCH1

Molecular functions related to Basal Cell Carcinoma 1 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 patched binding GO:0005113 9.56 SMO PTCH1
2 hedgehog family protein binding GO:0097108 9.46 PTCH2 PTCH1
3 hedgehog receptor activity GO:0008158 9.26 PTCH2 PTCH1
4 smoothened binding GO:0005119 8.92 PTCH2 PTCH1

Sources for Basal Cell Carcinoma 1

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....